New York, January 5, 2026, 21:51 EST — Market closed
- Pfizer said CEO Albert Bourla will speak at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, with a public webcast. 1
- Pfizer shares ended Monday down 0.04% at $25.17, near the middle of their $20.92-$27.69 52-week range. 2
- Next catalysts include Pfizer’s Feb. 3 earnings update and key U.S. data releases on Jan. 7 (ISM services PMI) and Jan. 9 (jobs report). 3
Pfizer said it will webcast a discussion with Chief Executive Albert Bourla at the J.P. Morgan Healthcare Conference next week, putting the drugmaker’s 2026 reset back in focus. Pfizer shares finished Monday little changed, down 0.04% at $25.17. 1
The San Francisco gathering is a major kickoff for healthcare investing, and it comes as Pfizer tries to convince markets it can replace fading pandemic-era revenue. The company’s initial 2026 outlook, issued in December, came in below analysts’ estimates. 4
That timing matters because Pfizer is navigating lower sales of its COVID-19 vaccine and treatment and approaching patent expirations on key drugs, pressures the company has said will weigh on the next few years. Investors are looking for a clearer path to sustained growth and steadier margins.
In a statement on Monday, Pfizer said Bourla will speak on Jan. 12 at 9:45 a.m. Pacific time and that a webcast will be available through its investor site. J.P. Morgan’s conference is scheduled for Jan. 12–15. 1
Pfizer stock has traded between $20.92 and $27.69 over the past 52 weeks, and it hit an intraday low of $24.95 on Monday before finishing near $25. The broader large-cap drugmaker group was mixed, with Merck up 0.9% and Johnson & Johnson down 1.5% on the day. 2
Pfizer in December projected 2026 adjusted earnings of $2.80 to $3.00 per share — “adjusted” meaning results that exclude certain items such as some acquisition-related costs — on revenue of $59.5 billion to $62.5 billion. At about $25 a share, that implies a forward price-to-earnings ratio of roughly 8 to 9.
“This stock is unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory,” Bernstein analyst Courtney Breen said in a Dec. 16 note. Pfizer has said it does not expect to return to revenue growth until 2029.
The next scheduled company update is Feb. 3, when Pfizer plans to publish its fourth-quarter and full-year 2025 performance report and host a conference call with analysts at 10 a.m. EST, the company said. Investors will scrutinize demand trends for products including Comirnaty and Paxlovid against management’s forecasts. 3
Pfizer has also declared a first-quarter 2026 dividend of $0.43 a share, payable March 6 to shareholders of record on Jan. 23, it said. At Monday’s close, that equates to an annual yield of about 6.8%. 5
Macro data could set the tone before Bourla takes the stage. The Institute for Supply Management is due to release its services PMI — a survey-based gauge where readings above 50 indicate expansion — on Jan. 7, followed by the U.S. jobs report for December on Jan. 9, according to ISM and the Labor Department. 6
But investors face the risk that conference remarks bring limited new numbers, while pricing concessions, patent expiries and higher R&D spending keep earnings under pressure in 2026. The next immediate test is Bourla’s Jan. 12 webcast at the J.P. Morgan Healthcare Conference, with Pfizer’s Feb. 3 earnings update close behind. 1
